Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin for depression, anxiety, cognitive function and sleep disturbances in breast cancer patients
2010-022460-12Phase 3Terminated
- Sponsor
- Herlev Hospital
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD), anxiety disorder, confusion and 1 more comparing Melatonin with Placebo (2 arms). Primary endpoint: Major Depression Inventory score. Started Feb 2011; status: terminated.
02
Drugs
melatonin
03
Conditions
major depressive disorder (MDD)anxiety disorderconfusionsleep disorder
Beyond the preview
Go deeper on 2010-022460-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022460-12.